GPIIb-IIIa antagonists modulate leukocyte-platelet aggregates in patients with ACS undergoing PCI

被引：0
|
作者：
Furman, MI [1 ]
Krueger, LA [1 ]
Barnard, MR [1 ]
Fox, ML [1 ]
Frelinger, AL [1 ]
Michelson, AD [1 ]
机构：
[1] Univ MA, Sch Med, Ctr Platelet Funct Study, Worcester, MA USA
来源：
CIRCULATION | 2002年 / 106卷 / 19期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2555
引用
收藏
页码：517 / 517
页数：1
相关论文
共 50 条
  • [11] GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Furman, MI
    Krueger, LA
    Linden, MD
    Fox, ML
    Ball, SP
    Barnard, MR
    Frelinger, AL
    Michelson, AD
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (02) : 312 - 320
  • [12] Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists
    Haga, JH
    Jennings, LK
    Slack, SM
    ANNALS OF BIOMEDICAL ENGINEERING, 2002, 30 (10) : 1262 - 1272
  • [13] Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists
    Sall, DJ
    Arfsten, AE
    Bastian, JA
    Denney, ML
    Harms, CS
    McCowan, JR
    Morin, JM
    Rose, JW
    Scarborough, RM
    Smyth, MS
    Um, SL
    Utterback, BG
    Vasileff, RT
    Wikel, JH
    Wyss, VL
    Jakubowski, JA
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (18) : 2843 - 2857
  • [14] Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation
    Frelinger, AL
    Furman, MI
    Barnard, MR
    Krueger, LA
    Dae, MW
    Michelson, AD
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (09): : 1099 - 1101
  • [15] Leukocyte-platelet aggregates in hyperlipidemic patients after ischemic stroke
    Pawelczyk, M.
    Chmielewski, H.
    Baj, Z.
    Chudzik, W.
    Kaczorowska, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 262 - 262
  • [16] Dissociation of GPIIb-IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
    Frelinger, AL
    Furman, MI
    Krueger, LA
    Barnard, MR
    Michelson, AD
    BLOOD, 1999, 94 (10) : 21A - 21A
  • [17] Increased platelet GPIIb-IIIa activation in type II diabetic patients is attenuated by aspirin
    Hokama, JY
    Gale, SC
    Logan, JJ
    Davis-Gorman, G
    Goldman, S
    Copeland, JG
    McDonagh, PF
    FASEB JOURNAL, 2000, 14 (04): : A671 - A671
  • [18] Greater inhibition of platelet procoagulant activity by antibody-derived GPIIb-IIIa antagonists than by peptide-derived or peptidomimetic antagonists
    Lages, B
    Weiss, HJ
    THROMBOSIS AND HAEMOSTASIS, 1999, : 638 - 638
  • [19] The use of the point of care Helena ICHOR/Plateletworks® and the accumetrics Ultegra® RPFA for assessment of platelet function with GPIIb-IIIa antagonists
    White, MM
    Krishnan, R
    Kueter, TJ
    Jacoski, MV
    Jennings, LK
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2005, 18 (03) : 163 - 169
  • [20] POTENT AND INTEGRIN SPECIFIC KGD-CONTAINING PLATELET ANTAGONISTS DESIGNED FROM THE GPIIB-IIIA SPECIFIC ANTAGONIST BARBOURIN
    SCARBOROUGH, RM
    HSU, MA
    TENG, W
    ROSE, JW
    NANNIZZI, L
    CAMPBELL, AM
    CHARO, IF
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 843 - 843
12345